Matt Miksic
Stock Analyst at Barclays
(3.78)
# 656
Out of 4,902 analysts
283
Total ratings
60.71%
Success rate
3.92%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $165 → $176 | $164.64 | +6.90% | 13 | Jul 17, 2025 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $19 → $16 | $14.09 | +13.59% | 5 | Jun 9, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $261 → $241 | $180.74 | +33.34% | 1 | Jun 3, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $56 → $55 | $42.38 | +29.78% | 7 | May 8, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $16 → $12 | $3.16 | +279.75% | 2 | May 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $90 → $93 | $84.08 | +10.61% | 6 | May 5, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $234 → $266 | $285.29 | -6.76% | 8 | Apr 30, 2025 | |
| INMD InMode | Maintains: Overweight | $29 → $24 | $14.04 | +70.94% | 13 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $125 | $104.20 | +19.96% | 17 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $684 → $635 | $518.97 | +22.36% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $125.01 | +27.19% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $27.83 | +47.32% | 21 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $53 | $15.05 | +252.16% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $57.23 | +79.98% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $90 | $77.10 | +16.73% | 28 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $94.43 | +18.61% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $390.68 | +13.39% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $10.59 | +98.30% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $3.17 | +595.10% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $89.76 | +21.43% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $8.55 | +87.24% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $87.38 | +9.86% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $69.20 | +44.52% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $189.33 | +120.78% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $11.08 | +152.71% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $15.80 | +324.05% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $10.40 | +4,515.38% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $11.53 | +654.55% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.42 | +465.61% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.65 | +35.34% | 1 | Dec 12, 2016 |
Johnson & Johnson
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $164.64
Upside: +6.90%
Bausch + Lomb
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $14.09
Upside: +13.59%
Becton, Dickinson and Company
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $180.74
Upside: +33.34%
LivaNova
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $55
Current: $42.38
Upside: +29.78%
Orchestra BioMed Holdings
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $3.16
Upside: +279.75%
DexCom
May 5, 2025
Maintains: Equal-Weight
Price Target: $90 → $93
Current: $84.08
Upside: +10.61%
Insulet
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $285.29
Upside: -6.76%
InMode
Apr 30, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $14.04
Upside: +70.94%
Boston Scientific
Apr 25, 2025
Maintains: Overweight
Price Target: $118 → $125
Current: $104.20
Upside: +19.96%
Intuitive Surgical
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $518.97
Upside: +22.36%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $125.01
Upside: +27.19%
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $27.83
Upside: +47.32%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $15.05
Upside: +252.16%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $57.23
Upside: +79.98%
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $77.10
Upside: +16.73%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $94.43
Upside: +18.61%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $390.68
Upside: +13.39%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.59
Upside: +98.30%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $3.17
Upside: +595.10%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $89.76
Upside: +21.43%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $8.55
Upside: +87.24%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $87.38
Upside: +9.86%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $69.20
Upside: +44.52%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $189.33
Upside: +120.78%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.08
Upside: +152.71%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $15.80
Upside: +324.05%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $10.40
Upside: +4,515.38%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $11.53
Upside: +654.55%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.42
Upside: +465.61%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.65
Upside: +35.34%